ArticleNorthern clinics of Istanbul2025
Pediatric inflammatory bowel diseases: Effects of disease and treatment regimens on growth and puberty.
Article in Northern clinics of Istanbul, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- [Prospects and mechanistic insights into the use of recombinant human growth hormone in the treatment of pediatric inflammatory bowel disease].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveInflammatory bowel diseases (IBD) are lifelong conditions that exhibit periods of remission and exacerbation. In addition to gastrointestinal manifestations, they can also cause growth retardation and disorders of puberty in children. The objective of this study was to evaluate the effects of the disease and the treatment regimens on growth and puberty in children and adolescents with IBD.
methodsA retrospective screening of patients aged 2 to 18 years with a minimum of six months of follow-up due to inflammatory bowel disease (IBD) between January 2016 and April 2022 was conducted. The growth parameters were compared between disease groups, gender groups, disease activity and level of inflammation groups, and treatment regimen groups. The effects of treatment protocols on growth were evaluated by comparing the data before and after treatment, and the pubertal status of patients was evaluated by comparing them with healthy children.
resultsA total of 58 patients were evaluated, comprising 29 individuals with Crohn's Disease (CD) and 29 with ulcerative colitis (UC). The growth and pubertal development of patients at the time of diagnosis did not differ based on gender or the specific disease type. A negative deviation from the target height was observed to be more prevalent in patients with Crohn's disease. Following treatment, patients exhibited a significant improvement in weight and BMI SDS, although no significant change in height SDS was observed. In comparison to healthy Turkish children, the patients exhibited a delayed pubertal progression, despite the normal onset of puberty.
conclusionChildren and adolescents with IBD exhibited no significant adverse effects on linear growth at diagnosis or during the follow-up period, regardless of the primary disease and the treatment protocols. This was likely due to their timely diagnosis and successful treatment. It is important to monitor puberty, as it may progress more slowly or even cease in these patients compared to healthy children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.